tetano
Editor, Senior Moderator
Front Immunol
. 2023 Mar 13;14:1064839.
doi: 10.3389/fimmu.2023.1064839. eCollection 2023.
A deep look into the storm: Israeli multi-center experience of coronavirus disease 2019 (COVID-19) in patients with autoimmune inflammatory rheumatic diseases before and after vaccinations
Fadi Kharouf[SUP] 1 2 [/SUP], Tali Eviatar[SUP] 3 4 [/SUP], Maya Braun[SUP] 2 [/SUP], Elisheva Pokroy-Shapira[SUP] 4 5 [/SUP], Michal Brodavka[SUP] 4 6 [/SUP], Yair Zloof[SUP] 2 [/SUP], Nancy Agmon-Levin[SUP] 4 7 [/SUP], Kochava Toledano[SUP] 8 9 [/SUP], Shirly Oren[SUP] 4 5 [/SUP], Merav Lidar[SUP] 4 6 [/SUP], Devy Zisman[SUP] 9 10 [/SUP], Yonit Tavor[SUP] 8 9 [/SUP], Mirit Amit-Vazina[SUP] 4 11 [/SUP], Firas Sabbah[SUP] 12 [/SUP], Gabriel S Breuer[SUP] 2 13 [/SUP], Amir Dagan[SUP] 4 14 [/SUP], Rima Beshara-Garzuzi[SUP] 9 10 [/SUP], Doron Markovits[SUP] 8 9 [/SUP], Muna Elias[SUP] 9 10 [/SUP], Joy Feld[SUP] 9 10 [/SUP], Oshrat Tayer-Shifman[SUP] 4 15 [/SUP], Tal Gazitt[SUP] 9 10 [/SUP], Tatiana Reitblatt[SUP] 16 [/SUP], Limor Rubin[SUP] 2 17 [/SUP], Amir Haddad[SUP] 9 10 [/SUP], Sami Giryes[SUP] 8 9 [/SUP], Daphna Paran[SUP] 3 4 [/SUP], Hagit Peleg[SUP] 1 2 [/SUP], Yair Molad[SUP] 4 5 [/SUP], Ori Elkayam[SUP] 3 4 [/SUP], Dror Mevorach[SUP] 1 2 [/SUP], Alexandra Balbir-Gurman[SUP] 8 9 [/SUP], Yolanda Braun-Moscovici[SUP] 8 9 [/SUP]
Affiliations
Abstract
Objective: We aimed to characterize the course of COVID-19 in autoimmune inflammatory rheumatic disease (AIIRD) patients in Israel, taking into consideration several remarkable aspects, including the outcomes of the different outbreaks, the effect of vaccination campaigns, and AIIRD activity post-recovery.
Methods: We established a national registry of AIIRD patients diagnosed with COVID-19, including demographic data, AIIRD diagnosis, duration and systemic involvement, comorbidities, date of COVID-19 diagnosis, clinical course, and dates of vaccinations. COVID-19 was diagnosed by a positive SARS-CoV-2 polymerase chain reaction.
Results: Israel experienced 4 outbreaks of COVID-19 until 30.11.2021. The first three outbreaks (1.3.2020 - 30.4.2021) comprised 298 AIIRD patients. 64.9% had a mild disease and 24.2% had a severe course; 161 (53.3%) patients were hospitalized, 27 (8.9%) died. The 4[SUP]th[/SUP] outbreak (delta variant), starting 6 months after the beginning of the vaccination campaign comprised 110 patients. Despite similar demographic and clinical characteristics, a smaller proportion of AIIRD patients had negative outcomes as compared to the first 3 outbreaks, with regards to severity (16 patients,14.5%), hospitalization (29 patients, 26.4%) and death (7 patients, 6.4%). COVID-19 did not seem to influence the AIIRD activity 1-3 months post-recovery.
Conclusions: COVID-19 is more severe and has an increased mortality in active AIIRD patients with systemic involvement, older age and comorbidities. Vaccination with 3 doses of the mRNA vaccine against SARS-CoV-2 protected from severe COVID-19, hospitalization and death during the 4[SUP]th[/SUP] outbreak. The pattern of spread of COVID-19 in AIIRD patients was similar to the general population.
Keywords: AIIRD; COVID-19, coronavirus disease 2019; SARS-CoV-2; autoimmune inflammatory rheumatic disease; outbreaks; severe acute respiratory syndrome coronavirus-2; vaccination.
. 2023 Mar 13;14:1064839.
doi: 10.3389/fimmu.2023.1064839. eCollection 2023.
A deep look into the storm: Israeli multi-center experience of coronavirus disease 2019 (COVID-19) in patients with autoimmune inflammatory rheumatic diseases before and after vaccinations
Fadi Kharouf[SUP] 1 2 [/SUP], Tali Eviatar[SUP] 3 4 [/SUP], Maya Braun[SUP] 2 [/SUP], Elisheva Pokroy-Shapira[SUP] 4 5 [/SUP], Michal Brodavka[SUP] 4 6 [/SUP], Yair Zloof[SUP] 2 [/SUP], Nancy Agmon-Levin[SUP] 4 7 [/SUP], Kochava Toledano[SUP] 8 9 [/SUP], Shirly Oren[SUP] 4 5 [/SUP], Merav Lidar[SUP] 4 6 [/SUP], Devy Zisman[SUP] 9 10 [/SUP], Yonit Tavor[SUP] 8 9 [/SUP], Mirit Amit-Vazina[SUP] 4 11 [/SUP], Firas Sabbah[SUP] 12 [/SUP], Gabriel S Breuer[SUP] 2 13 [/SUP], Amir Dagan[SUP] 4 14 [/SUP], Rima Beshara-Garzuzi[SUP] 9 10 [/SUP], Doron Markovits[SUP] 8 9 [/SUP], Muna Elias[SUP] 9 10 [/SUP], Joy Feld[SUP] 9 10 [/SUP], Oshrat Tayer-Shifman[SUP] 4 15 [/SUP], Tal Gazitt[SUP] 9 10 [/SUP], Tatiana Reitblatt[SUP] 16 [/SUP], Limor Rubin[SUP] 2 17 [/SUP], Amir Haddad[SUP] 9 10 [/SUP], Sami Giryes[SUP] 8 9 [/SUP], Daphna Paran[SUP] 3 4 [/SUP], Hagit Peleg[SUP] 1 2 [/SUP], Yair Molad[SUP] 4 5 [/SUP], Ori Elkayam[SUP] 3 4 [/SUP], Dror Mevorach[SUP] 1 2 [/SUP], Alexandra Balbir-Gurman[SUP] 8 9 [/SUP], Yolanda Braun-Moscovici[SUP] 8 9 [/SUP]
Affiliations
- PMID: 36993961
- PMCID: PMC10040776
- DOI: 10.3389/fimmu.2023.1064839
Abstract
Objective: We aimed to characterize the course of COVID-19 in autoimmune inflammatory rheumatic disease (AIIRD) patients in Israel, taking into consideration several remarkable aspects, including the outcomes of the different outbreaks, the effect of vaccination campaigns, and AIIRD activity post-recovery.
Methods: We established a national registry of AIIRD patients diagnosed with COVID-19, including demographic data, AIIRD diagnosis, duration and systemic involvement, comorbidities, date of COVID-19 diagnosis, clinical course, and dates of vaccinations. COVID-19 was diagnosed by a positive SARS-CoV-2 polymerase chain reaction.
Results: Israel experienced 4 outbreaks of COVID-19 until 30.11.2021. The first three outbreaks (1.3.2020 - 30.4.2021) comprised 298 AIIRD patients. 64.9% had a mild disease and 24.2% had a severe course; 161 (53.3%) patients were hospitalized, 27 (8.9%) died. The 4[SUP]th[/SUP] outbreak (delta variant), starting 6 months after the beginning of the vaccination campaign comprised 110 patients. Despite similar demographic and clinical characteristics, a smaller proportion of AIIRD patients had negative outcomes as compared to the first 3 outbreaks, with regards to severity (16 patients,14.5%), hospitalization (29 patients, 26.4%) and death (7 patients, 6.4%). COVID-19 did not seem to influence the AIIRD activity 1-3 months post-recovery.
Conclusions: COVID-19 is more severe and has an increased mortality in active AIIRD patients with systemic involvement, older age and comorbidities. Vaccination with 3 doses of the mRNA vaccine against SARS-CoV-2 protected from severe COVID-19, hospitalization and death during the 4[SUP]th[/SUP] outbreak. The pattern of spread of COVID-19 in AIIRD patients was similar to the general population.
Keywords: AIIRD; COVID-19, coronavirus disease 2019; SARS-CoV-2; autoimmune inflammatory rheumatic disease; outbreaks; severe acute respiratory syndrome coronavirus-2; vaccination.